DK0586002T3 - Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho - Google Patents
Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indehoInfo
- Publication number
- DK0586002T3 DK0586002T3 DK93202428T DK93202428T DK0586002T3 DK 0586002 T3 DK0586002 T3 DK 0586002T3 DK 93202428 T DK93202428 T DK 93202428T DK 93202428 T DK93202428 T DK 93202428T DK 0586002 T3 DK0586002 T3 DK 0586002T3
- Authority
- DK
- Denmark
- Prior art keywords
- monoclonal antibody
- egf
- tumor cells
- inhibiting
- growth factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1992100A CU22387A1 (es) | 1992-08-18 | 1992-08-18 | Anticuerpos monoclonados que reconocen el receptor del factor de crecimiento epidermico. procedimiento de obtencion |
| CU1993017 | 1993-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0586002T3 true DK0586002T3 (da) | 2000-06-19 |
Family
ID=25746823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93202428T DK0586002T3 (da) | 1992-08-18 | 1993-08-18 | Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0586002B1 (da) |
| AT (1) | ATE188874T1 (da) |
| DE (1) | DE69327620T2 (da) |
| DK (1) | DK0586002T3 (da) |
| ES (1) | ES2144440T3 (da) |
| GR (1) | GR3033290T3 (da) |
| PT (1) | PT586002E (da) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
| CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
| GB9405046D0 (en) * | 1994-03-15 | 1994-04-27 | Unilever Plc | Skin treatment composition |
| CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| EP0706799B1 (en) * | 1994-09-16 | 2001-11-14 | MERCK PATENT GmbH | Immunoconjugates II |
| IT1277827B1 (it) * | 1995-03-01 | 1997-11-12 | Ministero Uni Ricerca Scient E | Anticorpo monoclonale chimerico murino/umano o un suo frammento specifico per il recettore egf (egf-r) |
| EP0745612B1 (en) * | 1995-05-26 | 2001-11-07 | MERCK PATENT GmbH | Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor |
| DE69616651D1 (de) * | 1995-05-26 | 2001-12-13 | Merck Patent Gmbh | Antiidiotypische Antikörper die eine Immunantwort gegen den Rezeptor für epidermalen Wachstumsfaktor induzieren |
| US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| EP1278851B1 (en) * | 2000-05-19 | 2006-01-18 | Scancell Limited | Humanised antibodies to the epidermal growth factor receptor |
| CU22979A1 (es) * | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2002241922B2 (en) * | 2001-01-17 | 2007-10-25 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| CA2450285C (en) | 2001-06-13 | 2016-08-02 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| DE10355904A1 (de) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| PT1912675E (pt) | 2005-07-25 | 2014-05-09 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| US9090693B2 (en) | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| ES2542152T3 (es) | 2007-03-15 | 2015-07-31 | Ludwig Institute For Cancer Research Ltd. | Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas |
| JP5532486B2 (ja) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途 |
| CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
| EP2385955B1 (en) | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
| CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
| KR102329024B1 (ko) | 2013-12-23 | 2021-11-19 | 바이엘 파마 악티엔게젤샤프트 | 키네신 스핀들 단백질(ksp)과의 항체 약물 접합체 (adcs) |
| US10329348B2 (en) | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体(adc)および抗体プロドラッグ複合体(apdc) |
| AU2016282724A1 (en) | 2015-06-23 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | Targeted conjugates of KSP inhibitors |
| MY188446A (en) | 2015-07-27 | 2021-12-09 | Innocimab Pte Ltd | Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| IL291308B2 (en) | 2016-12-21 | 2024-07-01 | Bayer Pharma AG | Antibody drug conjugates (adcs) having enzymatically cleavable groups |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| CA3122191A1 (en) | 2018-12-26 | 2020-07-02 | Innate Pharma | Compounds and methods for treatment of head and neck cancer |
-
1993
- 1993-08-18 DK DK93202428T patent/DK0586002T3/da not_active Application Discontinuation
- 1993-08-18 PT PT93202428T patent/PT586002E/pt unknown
- 1993-08-18 DE DE69327620T patent/DE69327620T2/de not_active Expired - Lifetime
- 1993-08-18 ES ES93202428T patent/ES2144440T3/es not_active Expired - Lifetime
- 1993-08-18 EP EP93202428A patent/EP0586002B1/en not_active Expired - Lifetime
- 1993-08-18 AT AT93202428T patent/ATE188874T1/de active
-
2000
- 2000-04-20 GR GR20000400972T patent/GR3033290T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69327620D1 (de) | 2000-02-24 |
| EP0586002B1 (en) | 2000-01-19 |
| GR3033290T3 (en) | 2000-09-29 |
| PT586002E (pt) | 2000-07-31 |
| EP0586002A2 (en) | 1994-03-09 |
| ES2144440T3 (es) | 2000-06-16 |
| EP0586002A3 (en) | 1994-05-25 |
| DE69327620T2 (de) | 2000-08-03 |
| ATE188874T1 (de) | 2000-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0586002T3 (da) | Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho | |
| NZ210867A (en) | Tumour-specific monoclonal antibodies, production thereof and use | |
| PL311661A1 (en) | Single-chain anti-egfr fv and anti-egfr antibodies | |
| AU2190997A (en) | Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation | |
| WO1997019111A3 (es) | Anticuerpos monoclonales anti-cd6 y sus utilizaciones | |
| WO2001005425A3 (en) | Combined preparations comprising daunorubicin derivatives and her2 antibodies | |
| HUP0101160A2 (hu) | Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására | |
| MD1374G2 (ro) | Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică | |
| IL135221A0 (en) | Natural humanized antibody and methods for the preparation thereof | |
| EP0610201A4 (en) | FOR HUMAN TUMORNESCROSE FACTOR, SPECIFIC MONOCLONAL AND CHIMERAL ANTIBODIES. | |
| AU2308595A (en) | Monoclonal antibodies against hiv-1 and vaccines made thereo f | |
| MX9705349A (es) | Anticuerpo monoclonal 1a7 y su uso para el tratamiento de melanona y carcinoma de celulas pequeñas. | |
| MY137078A (en) | Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors. | |
| WO1996022373A3 (en) | Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma | |
| EP0198086A4 (en) | MAN-MOUSE HYBRIDOMA PRODUCING HUMAN ANTIVIRAL ANTIBODY, PREPARATION METHOD AND HUMAN ANTIVIRAL MONOCLONAL ANTIBODY. | |
| EP0194851A3 (en) | Human tumor therapy | |
| EP0166458A3 (en) | Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells | |
| BG51405A1 (en) | Hybridome cellular line secreting monoclonal antibody ageinst human erythrocytec blood group antigen b | |
| CS347190A3 (en) | Murine lymphocyte hybridoma tsh-116 producing monoclonal antibody of the class igg 2a against human thyrostimulative hormone | |
| CS347090A3 (en) | Murine lymphocyte hybridoma tsh-51 producing monoclonal antibody of the class igg 2a against human thyrostimulative hormone | |
| LTIP1867A (en) | Hybridoma producing murine monoclonal antibodies against human growth hormone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHB | Application shelved due to non-payment |